Flora Peyvandi Introduces Breakthrough Protease-Resistant ADAMTS13 Enhancing VWF Regulation in Thrombotic Disorders
A new study published in Blood Advances by Prof. Flora Peyvandi and colleagues presents a study about a bioengineered, protease-resistant form of ADAMTS13, designed to enhance resistance to proteolytic degradation without compromising its functional regulation of von Willebrand factor (VWF)-posted on X:
“Mortality, diagnosis, and etiology of disseminated intravascular coagulation – A systematic review and meta-analysis: Communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation.”
Recombinant ADAMTS13 has shown therapeutic potential in thrombotic disorders such as heritable TTP and is under investigation for use in acquired TTP and sickle cell disease. However, its susceptibility to degradation by proteases like plasmin limits its efficacy, especially under thrombo-inflammatory conditions. This study introduces protease-resistant ADAMTS13 variants—specifically modified in linker regions—that retain full VWF-cleaving function under flow. These stabilized forms resist cleavage by thrombin, FXIa, kallikrein, and neutrophil-derived enzymes, without compromising antithrombotic activity. The findings suggest that protease-resistant ADAMTS13 may enhance therapeutic durability in TTP and broaden its use in thrombosis-related diseases such as ischemic stroke and myocardial infarction.
Title: Development of a protease-resistant ADAMTS13 to improve stability against proteolytic degradation
Autors: Veronica DeYoung, Rex Huang, Hasam Madarati, Rida Malik, Peter Andrisani, Cherie Teney, Colin A. Kretz
Similar exciting news can be found in Hemostasis Today.
-
Jul 23, 2025, 15:42Uncovering the Hidden Signs of von Willebrand Disease
-
Jul 22, 2025, 17:19Wolfgang Miesbach Shares Newly Released Gene Therapy Qualification Criteria Paper
-
Jul 22, 2025, 17:05EAHAD Launches Europe-Wide Survey on Haemophilia Gene Therapy Readiness
-
Jul 22, 2025, 09:26Hemophilia of Georgia Highlights Participation in WFH 2025 Summit and Global Youth Training
-
Jul 22, 2025, 08:55tPA in Action: Quick‑Guide to Alteplase Dosage for Common Thrombotic Emergencies
-
Jul 22, 2025, 09:17Decoding Antiphospholipid Syndrome: Why Triple Positivity Is a Red Flag for Thrombosis
-
Jul 21, 2025, 16:24Code I26: A Precise Tool to Strengthen VTE Surveillance
-
Jul 20, 2025, 17:12Thromboelastography: Coagulation Beyond INR and aPTT
-
Jul 20, 2025, 16:555 Crucial Insights into Low VWF QL: Uncovering a Distinct Cause of Bleeding
-
Jul 19, 2025, 17:16Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 23, 2025, 15:34Don't Miss the Hemophilia B Virtual Event on July 29 – Sign Up Now!
-
Jul 23, 2025, 11:05Haemnet Gives Voice to Parents Facing the Challenges of Childhood Bleeding Disorders
-
Jul 23, 2025, 10:43From Blood Clot Survivor to NFL History: Trey Smith’s Record Deal
-
Jul 22, 2025, 16:48How Children See Blood Clots: World Thrombosis Day Shares Artwork from Young Artists
-
Jul 22, 2025, 08:48NBCA: From Marathon Dreams to ICU — Sam’s Blood Clot Wake-Up Call